HARBOR 2-year results support individualized dosing

TORONTO — Two-year results of the HARBOR trial support as-needed treatment in patients with wet age-related macular degeneration, a researcher said here. “Over 2 years, 93% of PRN [as needed] patients did not require monthly dosing, indicating that an individualized treatment approach with ranibizumab may be appropriate for most patients with wet macular degeneration,” Brandon Busbee, MD, said at the American Society of Retina Specialists meeting.In the HARBOR trial, 1,097 patients with active disease were randomized to one of four groups: 0.5 mg or 2 mg ranibizumab injected monthly, or 0.5 mg (Read more...)

Full Story →